A phase 2 signal highlighted antibody performance in immune thrombocytopenia (ITP). The investigational antibody mezagitamab significantly increased platelet counts in patients in a Phase 2 trial, supporting further development in a disease defined by autoimmune-driven low platelet levels. On the enabling side of targeted biologics development, Agilent highlighted how lab automation is being used to scale antibody-drug conjugate (ADC) characterization for faster, more reproducible targeted biologic development. For developers, improved characterization throughput can shorten iteration cycles across ADC structure–activity work and reduce variability. The combination of clinical efficacy updates and platform/process upgrades underscores how biotech programs are pairing patient data with manufacturing and analytics improvements to compress timelines.